Everyday cognitive failure in sarcoidosis: The prevalence and the effect of anti-TNF-α treatment

Respiration

Volumn 80, Issue 3, 2010, Pages 212-219

  Elfferich, Marjon D ^a,b   Nelemans, Patty J ^a,b   Ponds, Rudolf W ^a,b   De Vries, Jolanda ^a,c,d   Wijnen, Petal A ^a   Drent, Marjolein ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

Author keywords

Adalimumab; Anti TNF therapy; Cognitive function; Infliximab; Neuropsychological deficits; Sarcoidosis

Indexed keywords

ADALIMUMAB; ANTIDEPRESSANT AGENT; CORTICOSTEROID; FOLIC ACID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SARCOIDOSIS; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PREVALENCE; SARCOIDOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955034395     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314225     Document Type: Article

References (29)

1. Hung WW, Wisnivesky JP, Siu AL, Ross JS: Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180 : 134-137.
2. Bargagli E, Maggiorelli C, Rottoli P: Human chitotriosidase: a potential new marker of sarcoidosis severity. Respiration 2008; 76: 234-238.
3. Handa T, Nagai S, Hirai T, Chin K, Kubo T, Oga T, Niimi A, Matsumoto H, Ito Y, Taka-hashi K, Watanabe K, Izumi T, Mishima M: Computed tomography analysis of airway dimensions and lung density in patients with sarcoidosis. Respiration 2009; 77:273-281.
4. Rothkrantz-Kos S, Van Dieijen-Visser MP, Mulder PG, Drent M: Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49:1510-1517.
5. Wijnen PA, Nelemans PJ, Verschakelen JA, Bekers O, Voorter CE, Drent M: The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sar-coidosis. Tissue Antigens 2010; 75: 262-268.
6. Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 2007; 357:2153-2165.
7. Drent M, Wirnsberger RM, Breteler MH, Kock LM, De Vries J, Wouters EF: Quality of l ife a nd depre ssive sy mptoms in patient ssu f-fering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 59-66.
8. Wirnsberger RM, De Vries J, Breteler MH, Van Heck GL, Wouters EF, Drent M: Evaluation of quality of life in sarcoidosis patients. Respir Med 1998; 92: 750-756.
9. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA: Health-related quality of life of persons with sarcoidosis. Chest 2004; 125: 997-1004.
10. Chang B, Steimel J, Moller DR, Baughman R P, Judson MA, Yeager H Jr, Teirstein AS, Rossman MD, Rand CS: Depression in sar-coidosis. Am J Respir Crit Care Med 2001; 163:329-334.
11. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR: The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982; 21:1-16.
12. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-755.
13. Van Boxtel MP, Buntinx F, Houx PJ, Metse-makers JF, Knottnerus A, Jolles J: The relation between morbidity and cognitive performance in a normal aging population. J Gerontol A Biol Sci Med Sci 1998; 53:M147-M154.
14. Michielsen HJ, De Vries J, Drent M, Peros-Golubicic T: Psychometric qualities of the Fatigue Assessment Scale in Croatian sar-coidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 133-138.
15. De Vries J, Michielsen H, Van Heck GL, Drent M: Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Hea lth Psychol 20 04; 9: 279-291.
16. Radloff L: The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1:385-401.
17. Hoitsma E: Small Fiber Neuropathy. A Novel Finding in Sarcoidosis; thesis. Maastricht: University of Maastricht, 2005.
18. McAfoose J, Baune BT: Evidence for a cyto-kine model of cognitive function. Neurosci Biobehav Rev 2009; 33: 355-366.
19. Hoitsma E, Faber CG, Drent M, Sharma OP: Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3: 397-407.
20. Baune BT, Wiede F, Braun A, Golledge J, Arolt V, Koerner H: Cognitive dysfunction in mice deficient for TNF-and its receptors. Am J Med Genet B Neuropsychiatr Genet 2008; 147 B:1056-1064.
21. Tobinick EL, Gross H: Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neu-roinf La mmation 2008; 5: 2.
22. Alkam T, Nitta A, Mizoguchi H, Saito K, Se-shima M, Itoh A, Yamada K, Nabeshima T: Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res 2008; 189 : 100-106.
23. Baughman R P, Lower EE, Drent M: Inhibitors of tumor necrosis factor (TNF) in sar-coidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 76-89.
24. Baughman R P, Drent M, Kavuru M, Judson MA, Costabel U, Du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795-802.
25. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W Jr, Sands BE: A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sa rcoidosis Vasc Diff use Lung Dis 2006; 23: 201-208.
26. Moravan M, Segal BM: Treatment of CNS sarcoidosis with infliximab and mycophe-nolate mofetil. Neurology 2009; 72:337-340.
27. Hoitsma E, Faber CG, Van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M: Improvement of small fiber neuropathy in a sarcoid-osis patient after treatment with infliximab. Sa rcoidosis Vasc Diff use Lung Dis 2006; 23: 73-77.
28. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE: Thalidomide for chronic sarcoidosis. Chest 2002; 122:227-232.
29. Ponds RW, Commissaris KJ, Jolles J: Prevalence and covariates of subjective forgetful-ness in a normal population in The Netherlands. Int J Aging Hum Dev 1997; 45:207-221.